Southwest Florida angels invested $360,000 in Aperiomics, a health technology firm that can identify every known microorganism in a clinical sample with just one test.
NAPLES, Fla. (December 10, 2020) — A group of angel investors from Southwest Florida invested in Aperiomics, a pathogen-testing company that can identify as many as 40,000 microorganisms in a single test.
Members of Tamiami Angel Fund IV invested $360,000 in Aperiomics. This is the 30th company in the Tamiami Angel Funds portfolio and the first investment for the members of its newest fund, Tamiami Angel Fund IV.
“Aperiomics is changing everything about how infections are identified. We are excited about the company’s groundbreaking genetic-based technology that uses big data to revolutionize microbial identification and improve human health,” said Timothy Cartwright, partner of Fifth Avenue Family Office and chairman of Tamiami Angel Funds.
Most tests today can only identify a few microbes at a time, incapable of giving the answers that patients and physicians seek. To solve that problem, Aperiomics developed a technology that identifies every known bacterium, virus, fungus and parasite through deep metagenomic sequencing, using its proprietary, world-renowned database containing nearly 40,000 microorganisms. The results from this test can help doctors and their patients identify the causes of infections that other tests cannot, streamlining the path to a positive clinical outcome.
“Aperiomics is extraordinarily grateful to work alongside the Tamiami Angel Funds to fundamentally shift the paradigm of infectious disease testing,” said Dr. Crystal Icenhour, CEO of Aperiomics. “Leveraging Tamiami’s expertise and resources, our team will be well-positioned to accelerate our advanced DNA metagenomic sequencing technology to become the diagnostic standard of care.”
About Aperiomics
The only company of its kind and scope in the world combining advanced DNA testing, the power of big data and decades of infectious disease expertise, Aperiomics is revolutionizing the way that medical professionals around the world identify infections. Supported by the National Science Foundation, Aperiomics identifies every known bacterium, virus, fungus, and parasite through deep shotgun metagenomic sequencing, using its proprietary, world-renowned database containing nearly 40,000 microorganisms. Helping doctors and their patients identify the causes of infections that other tests cannot identify, Aperiomics streamlines the path to a positive clinical outcome. Aperiomics was named Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018. www.aperiomics.com
NAPLES, Fla. (December 10, 2020) — A group of angel investors from Southwest Florida invested in Aperiomics, a pathogen-testing company that can identify as many as 40,000 microorganisms in a single test.
Members of Tamiami Angel Fund IV invested $360,000 in Aperiomics. This is the 30th company in the Tamiami Angel Funds portfolio and the first investment for the members of its newest fund, Tamiami Angel Fund IV.
“Aperiomics is changing everything about how infections are identified. We are excited about the company’s groundbreaking genetic-based technology that uses big data to revolutionize microbial identification and improve human health,” said Timothy Cartwright, partner of Fifth Avenue Family Office and chairman of Tamiami Angel Funds.
Most tests today can only identify a few microbes at a time, incapable of giving the answers that patients and physicians seek. To solve that problem, Aperiomics developed a technology that identifies every known bacterium, virus, fungus and parasite through deep metagenomic sequencing, using its proprietary, world-renowned database containing nearly 40,000 microorganisms. The results from this test can help doctors and their patients identify the causes of infections that other tests cannot, streamlining the path to a positive clinical outcome.
“Aperiomics is extraordinarily grateful to work alongside the Tamiami Angel Funds to fundamentally shift the paradigm of infectious disease testing,” said Dr. Crystal Icenhour, CEO of Aperiomics. “Leveraging Tamiami’s expertise and resources, our team will be well-positioned to accelerate our advanced DNA metagenomic sequencing technology to become the diagnostic standard of care.”
About Aperiomics
The only company of its kind and scope in the world combining advanced DNA testing, the power of big data and decades of infectious disease expertise, Aperiomics is revolutionizing the way that medical professionals around the world identify infections. Supported by the National Science Foundation, Aperiomics identifies every known bacterium, virus, fungus, and parasite through deep shotgun metagenomic sequencing, using its proprietary, world-renowned database containing nearly 40,000 microorganisms. Helping doctors and their patients identify the causes of infections that other tests cannot identify, Aperiomics streamlines the path to a positive clinical outcome. Aperiomics was named Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018. www.aperiomics.com
RSS Feed
